According to the latest UK Unemployment news, the United Kingdom has announced plans to offer weight-loss jabs to unemployed individuals suffering from obesity to address rising unemployment, enhance health outcomes and stimulate the economy. This initiative was spearheaded by UK Health Secretary Wes Streeting.
Also Read: New Study Reveals Over 600 Viruses Found on Showerheads, Toothbrushes
According to the latest UK Unemployment news, Wes Streeting’s initiative will introduce weight-loss jabs specifically the drug Mounjaro, to tackle obesity in unemployed individuals with the goal of increasing their employability and contributing to the national economy.
Mounjaro produced by Eli Lilly is already used for managing Type 2 diabetes and weight loss, but the new trials will investigate its impact on unemployment and economic productivity.
The UK has been dubbed the fat man of Europe, with rising rates of obesity causing concern. According to the latest UK Unemployment news, 29% of adults in England were classified as obese in 2022 and 64% were either overweight or obese.
Obesity-related illnesses cost the NHS £11 billion annually surpassing the economic impact of smoking.
Obesity contributes to an average of four extra sick days per year per person and for many, it leads to absence from the workforce.
The initiative is part of a £279 million investment by Eli Lilly into the UK life sciences sector focusing on developing new treatments and healthcare innovations.
The pharmaceutical giant will conduct the world’s first real-world trial on the effects of weight-loss jabs on unemployed individuals, their productivity and reliance on the NHS.
Greater Manchester has been selected as the site for this trial. The city-region currently experiences £3.2 billion in annual economic losses due to obesity with roughly half attributed to reduced productivity.
According to the latest UK Unemployment news, the trial will focus on the drug tirzepatide branded as Mounjaro, which is known for its efficacy in managing weight. Dubbed the King Kong of fat-busting injections, Mounjaro is the most effective drug on the market for weight loss.
By providing these jabs to unemployed individuals diagnosed with obesity, the trial will evaluate how weight loss affects employability, productivity and healthcare costs.
The trial will run for five years, with up to 3,000 participants, as the government aims to gather concrete evidence of the drug’s effects.
According to the latest UK Unemployment news, Obesity is the second-largest preventable cause of cancer and is a major factor in life-threatening conditions including heart attacks and strokes.
According to UK Unemployment news, the NHS is currently overwhelmed by obesity-related health issues. This weight-loss initiative is expected to ease the burden on the NHS, reducing costs and freeing up resources for other areas of healthcare.
Amanda Pritchard, Chief Executive of the NHS praised weight-loss jabs as game-changers in the fight against obesity.
Also Read: Breakdancers Warned to Many Headspins Could Give them a Cone-Head
According to UK Unemployment news, providing these weight loss injections could bring economic benefits. Obesity-related illnesses cost the NHS £11 billion a year and reducing the obesity rate would alleviate this burden on public health services.
Many people are forced out of work due to obesity-related health problems and the new initiative aims to help them regain their ability to work.
By reducing obesity levels, the government hopes to lower the number of sick days taken by individuals due to obesity-related health issues. Currently, obesity causes workers to take an average of four extra sick days per year.
The NHS already prescribes some weight loss jabs such as Wegovy and Ozempic, for obesity and diabetes treatment. These drugs suppress appetite, making individuals feel fuller for longer.
As the demand for these drugs is expected to rise, the NHS has proposed a roll-out to accommodate the high levels of anticipated demand across England.
Nearly 250,000 people are projected to receive the Mounjaro jab, a new weight-loss treatment, over the next three years, as of the latest UK Unemployment news updates.
A five-year study will be conducted in Greater Manchester by Health Innovation Manchester in collaboration with the pharmaceutical company Lilly.
The study will examine the effectiveness of the Mounjaro jab in reducing worklessness and its impact on the healthcare system including the number of sick days taken by individuals.
According to the latest UK Unemployment news, UK Prime Minister Sir Keir Starmer voiced his support for this initiative. He addressed the need for new, innovative approaches to reducing pressure on the NHS and acknowledged the necessity for more funding for public health services.
Starmer also addressed that in addition to increased NHS funding, the government must think differently about how to tackle systemic health and employment issues in the UK.
With nearly a quarter of a million people expected to receive the Mounjaro jab over the next three years.
The jabs will initially be offered to individuals with severe obesity specifically those with a body mass index over 40 and who have multiple health conditions related to their weight. This includes conditions like heart disease, high blood pressure and obstructive sleep apnoea.
Also Read: COVID-19 Increases Risk of Heart Attack and Stroke for Up to 3 Years
